INT83734

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.50
First Reported 1999
Last Reported 2010
Negated 0
Speculated 3
Reported most in Body
Documents 24
Total Number 33
Disease Relevance 35.75
Pain Relevance 5.66

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
substantia nigra 1
liver 1
superior 1
legs 1
ergot 1
RLS (Homo sapiens)
Pain Link Frequency Relevance Heat
Restless leg syndrome 14 100.00 Very High Very High Very High
Gabapentin 195 99.58 Very High Very High Very High
Oxycodone 4 99.14 Very High Very High Very High
Migraine 12 97.64 Very High Very High Very High
agonist 203 97.58 Very High Very High Very High
cva 161 97.56 Very High Very High Very High
dopamine receptor 25 94.40 High High
Opioid 27 94.24 High High
anticonvulsant 13 93.52 High High
methadone 6 92.40 High High
Disease Link Frequency Relevance Heat
Restless Legs Syndrome 2211 100.00 Very High Very High Very High
Movement Disorders 63 100.00 Very High Very High Very High
Cadasil 4 100.00 Very High Very High Very High
Stroke 305 99.86 Very High Very High Very High
Patent Foramen Ovale 373 99.84 Very High Very High Very High
Disease Susceptibility 2 99.76 Very High Very High Very High
Attention Deficit Hyperactivity Disorder 46 99.72 Very High Very High Very High
Syncope 5 98.68 Very High Very High Very High
Increased Venous Pressure Under Development 16 98.14 Very High Very High Very High
Pulmonary Embolism 70 97.96 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
RESULTS: Results indicated that relative to placebo, ropinirole, at a mean dose of 1.4mg HS significantly decreased PLMS and RLS symptoms.
Negative_regulation (decreased) of RLS
1) Confidence 0.50 Published 2005 Journal Sleep Med. Section Body Doc Link 15716217 Disease Relevance 0.07 Pain Relevance 0
Massaging the affected legs, taking hot baths, and performing mentally demanding tasks have been reported to reduce RLS symptoms.
Negative_regulation (reduce) of RLS in legs associated with restless legs syndrome
2) Confidence 0.50 Published 2009 Journal Brain Nerve Section Abstract Doc Link 19514515 Disease Relevance 1.10 Pain Relevance 0.37
A similar pattern was observed for antidepressants in the RLS cohort (23.5%, 26.7%, 31.0%, and 29.6%, respectively; P < 0.001).
Negative_regulation (antidepressants) of RLS
3) Confidence 0.37 Published 2008 Journal Clin Ther Section Body Doc Link 18343278 Disease Relevance 0 Pain Relevance 0
At a mean dose of 1.4 mg, ropinirole significantly decreased RLS severity and PLMS without changing sleep parameters.
Negative_regulation (decreased) of RLS associated with restless legs syndrome
4) Confidence 0.37 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671939 Disease Relevance 0.67 Pain Relevance 0.06
RLS sufferers represent 2 to 3% of the general population in Western countries.
Negative_regulation (represent) of RLS associated with restless legs syndrome
5) Confidence 0.36 Published 2008 Journal Rev. Neurol. (Paris) Section Abstract Doc Link 18656214 Disease Relevance 0.80 Pain Relevance 0.04
In addition, a treatment able to remove the main clinical condition (such as iron supplements and kidney transplantation) may produce a complete remission of RLS symptomatology.
Negative_regulation (remission) of RLS in kidney associated with restless legs syndrome
6) Confidence 0.35 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695234 Disease Relevance 1.57 Pain Relevance 0.08
The International RLS Rating Scale (IRLS) seems to cover more appropriately the clinical spectrum of RLS, it has some limitations, being prone to a placebo effect (see section “Management of RLS with rotigotine”) and only partially evaluating RLS consequences on QoL.
Negative_regulation (evaluating) of RLS associated with restless legs syndrome
7) Confidence 0.35 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695234 Disease Relevance 1.69 Pain Relevance 0
Despite the large placebo effect (responder rate of 42%) treatment with rotigotine in the therapeutic window cited above was demonstrated to be statistically superior in reducing RLS symptoms.
Negative_regulation (reducing) of RLS in superior associated with restless legs syndrome
8) Confidence 0.35 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695234 Disease Relevance 0.52 Pain Relevance 0
Vasodilation is also the result of exercise [18], one of the few non-drug related treatment options that decreases RLS symptoms.
Negative_regulation (decreases) of RLS associated with restless legs syndrome and increased venous pressure under development
9) Confidence 0.33 Published 2010 Journal J Med Case Reports Section Body Doc Link PMC2936319 Disease Relevance 0.76 Pain Relevance 0.05
In double-blind, placebo-controlled trials, several workers have reported the beneficial effects of drugs such as oxycodone and propoxyphone in providing symptomatic relief of both RLS and PLMS (Allen et al 1992; Walters et al 1993; Henning et al 1999).
Negative_regulation (relief) of RLS associated with oxycodone and restless legs syndrome
10) Confidence 0.28 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671772 Disease Relevance 0.92 Pain Relevance 1.16
Later studies consistently showed the beneficial effects of levodopa given with a peripheral decarboxylase inhibitor in both primary and also secondary RLS patients (Brodeur et al 1988; Von Scheele and Kempi 1990; Trenkwalder et al 1995).
Negative_regulation (inhibitor) of RLS associated with restless legs syndrome
11) Confidence 0.28 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671938 Disease Relevance 1.35 Pain Relevance 0.26
However, although D2-receptor agonists of ergot derivatives, such as bromocriptine (Walters et al 1988) and pergolide (Earley and Allen 1997), are shown to be effective in RLS, some major and frequent side-effects limit their usefulness.
Negative_regulation (effective) of RLS in ergot associated with agonist and restless legs syndrome
12) Confidence 0.28 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671938 Disease Relevance 0.62 Pain Relevance 0.35
In a randomized, double-blind, placebo-controlled trial involving 63 patients with RLS, rotigotine significantly reduced RLS severity scores compared with placebo at 4.5 mg daily dose (Stiasny-Kolster et al 2002; Stiasny-Kolster, Kohnen, et al 2004).
Negative_regulation (reduced) of RLS associated with restless legs syndrome
13) Confidence 0.28 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671772 Disease Relevance 0.76 Pain Relevance 0.12
High prevalence of RLS symptoms in children with ADHD and PLMS has also been reported (Picchietti et al 1998).
Negative_regulation (prevalence) of RLS associated with attention deficit hyperactivity disorder and restless legs syndrome
14) Confidence 0.27 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671938 Disease Relevance 1.74 Pain Relevance 0
The overall efficacy was a 50% reduction of RLS symptoms while receiving ropinirole based on RLS scores and the diary.
Negative_regulation (reduction) of RLS associated with restless legs syndrome
15) Confidence 0.26 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2857615 Disease Relevance 1.30 Pain Relevance 0
A German study [26] discovered significant evidence for an association of RLS with sequence variations in the NOS1 gene, pointing to a possible involvement of the NO/arginine pathway in RLS disease susceptibility and in the etiology of RLS.
Spec (possible) Negative_regulation (etiology) of RLS associated with disease susceptibility and restless legs syndrome
16) Confidence 0.24 Published 2010 Journal J Med Case Reports Section Body Doc Link PMC2936319 Disease Relevance 1.00 Pain Relevance 0.27
Patients treated with gabapentin enacarbil showed an improved international RLS (IRLS) total score (?
Negative_regulation (improved) of RLS associated with restless legs syndrome and gabapentin
17) Confidence 0.24 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2874339 Disease Relevance 0.85 Pain Relevance 0.67
This group of medications is effective in reducing RLS symptoms in the general population; limited information is available on the effect of these drugs in patients with renal failure.
Negative_regulation (reducing) of RLS associated with renal failure and restless legs syndrome
18) Confidence 0.23 Published 2006 Journal Drugs Section Abstract Doc Link 16620140 Disease Relevance 0.87 Pain Relevance 0.15
For example, oral iron supplementation decreased RLS scores when serum ferritin levels were below 0.45 pg/mL, but did not seem to have such beneficial effect on RLS symptoms when ferritin levels were higher, albeit decreased compared to control subjects.17 Despite such findings, serum ferritin levels were correlated with RLS score.17,18 However, such association could not be reproduced in a larger epidemiologic study.19 Earley and co-workers suggested that iron deficiency in the central nervous system, rather than in the peripheral blood was correlated with RLS symptoms based on CSF studies from 16 patients and 8 control subjects.20 Indeed, CSF levels of ferritin were significantly lower in the study group (mean 1.11 ± 0.25 ng/mL vs 3.50 ± 0.55 ng/mL, P = 0.0002) versus controls.20 Also, imaging studies using T2-weighted MRI and post-mortem brain studies have found decreased levels of iron in the substantia nigra.21,22 Snyder et al assessed neuronal staining patterns of ferritin in the human brain, and found increased mitochondrial levels of ferritin in the substantia nigra of patients with RLS compared to controls.
Negative_regulation (decreased) of RLS in substantia nigra associated with anaemia, substantia nigra, central nervous system, restless legs syndrome and imagery
19) Confidence 0.19 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2857615 Disease Relevance 1.41 Pain Relevance 0.24
In the treatment group, a significant decrease in PLMS and RLS symptoms was noted.
Negative_regulation (decrease) of RLS associated with restless legs syndrome
20) Confidence 0.19 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2857615 Disease Relevance 0.55 Pain Relevance 0.12

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox